Renaissance Technologies (RenTech)'s ATRC Position Overview
Renaissance Technologies (RenTech) (via Renaissance Technologies LLC) currently holds 308,700 shares of AtriCure, Inc. (ATRC) worth $8.81 M, representing 0.01% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 46 quarters.
Based on 13F filings since 2013, Renaissance Technologies (RenTech) has maintained a long-term strategic position in ATRC, representing a significant commitment to this investment thesis. Largest addition occurred in Q1 2020, adding 211,300 shares. Largest reduction occurred in Q4 2020, reducing 550,475 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies (RenTech)'s AtriCure (ATRC) Holding Value Over Time
Track share changes against reported price movement
Quarterly AtriCure (ATRC) Trades by Renaissance Technologies (RenTech)
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | -13,200 | Reduce 4.10% | 308,700 | $28.53 |
| Q4 2025 | +63,100 | Add 24.38% | 321,900 | $39.56 |
| Q3 2025 | -118,900 | Reduce 31.48% | 258,800 | $35.25 |
| Q2 2025 | +69,800 | Add 22.67% | 377,700 | $32.77 |
| Q1 2025 | +144,000 | Add 87.86% | 307,900 | $32.26 |
| Q4 2024 | +65,800 | Add 67.07% | 163,900 | $30.56 |
| Q3 2024 | -73,600 | Reduce 42.87% | 98,100 | $28.04 |
| Q2 2024 | +19,500 | Add 12.81% | 171,700 | $22.77 |
| Q1 2024 | +57,900 | Add 61.40% | 152,200 | $30.42 |
| Q4 2023 | -47,100 | Reduce 33.31% | 94,300 | $35.69 |
| Q3 2023 | +44,600 | Add 46.07% | 141,400 | $43.80 |
| Q2 2023 | -37,900 | Reduce 28.14% | 96,800 | $0.05 |
| Q1 2023 | +35,900 | Add 36.34% | 134,700 | $0.04 |
| Q4 2022 | -11,000 | Reduce 10.02% | 98,800 | $0.04 |
| Q3 2022 | +29,700 | Add 37.08% | 109,800 | $39.10 |
| Q2 2022 | +80,100 | New Buy | 80,100 | $40.86 |
| Q4 2021 | -65,200 | Sold Out | 0 | $0.00 |
| Q3 2021 | -3,400 | Reduce 4.96% | 65,200 | $69.56 |
| Q2 2021 | +68,600 | New Buy | 68,600 | $79.33 |
| Q1 2021 | -20,900 | Sold Out | 0 | $0.00 |
| Q4 2020 | -550,475 | Reduce 96.34% | 20,900 | $55.69 |
| Q3 2020 | -102,100 | Reduce 15.16% | 571,375 | $39.90 |
| Q2 2020 | +138,975 | Add 26.00% | 673,475 | $44.95 |
| Q1 2020 | +211,300 | Add 65.38% | 534,500 | $33.59 |
| Q4 2019 | +115,700 | Add 55.76% | 323,200 | $32.51 |
| Q3 2019 | +32,259 | Add 18.41% | 207,500 | $24.94 |
| Q2 2019 | +45,541 | Add 35.11% | 175,241 | $29.84 |
| Q1 2019 | +99,500 | Add 329.47% | 129,700 | $26.79 |
| Q4 2018 | +8,600 | Add 39.81% | 30,200 | $30.60 |
| Q3 2018 | -43,100 | Reduce 66.62% | 21,600 | $35.05 |
| Q2 2018 | +900 | Add 1.41% | 64,700 | $27.05 |
| Q1 2018 | -12,229 | Reduce 16.08% | 63,800 | $20.52 |
| Q4 2017 | +51,429 | Add 209.06% | 76,029 | $18.24 |
| Q3 2017 | +24,600 | New Buy | 24,600 | $22.36 |
| Q1 2017 | -57,200 | Sold Out | 0 | $0.00 |
| Q4 2016 | -31,700 | Reduce 35.66% | 57,200 | $19.56 |
| Q3 2016 | -1,700 | Reduce 1.88% | 88,900 | $15.82 |
| Q2 2016 | -24,200 | Reduce 21.08% | 90,600 | $14.13 |
| Q1 2016 | +114,800 | New Buy | 114,800 | $16.83 |
| Q4 2015 | -18,500 | Sold Out | 0 | $0.00 |
| Q3 2015 | +18,500 | New Buy | 18,500 | $21.89 |
| Q2 2014 | -38,950 | Sold Out | 0 | $0.00 |
| Q1 2014 | +7,250 | Add 22.87% | 38,950 | $18.82 |
| Q4 2013 | +31,700 | New Buy | 31,700 | $18.68 |
| Q3 2013 | -35,320 | Sold Out | 0 | $0.00 |
| Q2 2013 | +35,320 | Add 0.00% | 35,320 | $9.51 |
Renaissance Technologies (RenTech)'s AtriCure Investment FAQs
Renaissance Technologies (RenTech) first purchased AtriCure, Inc. (ATRC) in Q2 2013, acquiring 35,320 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies (RenTech) has held AtriCure, Inc. (ATRC) for 46 quarters since Q2 2013.
Renaissance Technologies (RenTech)'s largest addition to AtriCure, Inc. (ATRC) was in Q1 2020, adding 534,500 shares worth $17.95 M.
According to the latest 13F filing for Q1 2026, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC, owns 308,700 shares of AtriCure, Inc. (ATRC), valued at approximately $8.81 M.
As of the Q1 2026 filing, AtriCure, Inc. (ATRC) represents approximately 0.01% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies (RenTech)'s peak holding in AtriCure, Inc. (ATRC) was 673,475 shares, as reported at the end of Q2 2020.